



Xellia Pharmaceuticals announces a new three-year collaboration agreement with SOS Children's Villages, Denmark

Copenhagen, Denmark, 9 February 2021 - Xellia Pharmaceuticals ('Xellia'), is pleased to announce that it has signed a new three-year collaboration agreement with SOS Children's Villages, Denmark ('SOS DK') for 2021-2023 to support the Family Strengthening Program ('FS Program') in Eldoret, Kenya.

SOS Children's Villages ('SOS') is the world's largest non-governmental organisation focused on supporting children without parental care and families at risk. The Xellia collaboration with SOS DK, began in 2015, with a partnership in support of the SOS Medical Center in Eldoret, Kenya.

In the new three-year collaboration agreement, Xellia has pledged to fund activities and outreach campaigns coordinated by the SOS FS Program in Eldoret, Kenya. The Program is intended to support families experiencing crisis or extreme hardships that may have difficulty in caring for their children, by building the financial and social competences of the caregivers, and strengthening community-based partners to create a strong safety net around the vulnerable children and youth in the community. Whilst helping build these competencies, the Program provides the families with access to essential healthcare and education as well as assistance with vital everyday needs; this can include materials for their shelter and daily living, while the most vulnerable families receive supplementary rations of the necessary food types. Through funding, the partnership will allow Xellia to help improve the lives of over 70 vulnerable families in the local Eldoret community each year.

Carl-Åke Carlsson, CEO & President, Xellia Pharmaceuticals said: *"At Xellia, our purpose is to save and enhance lives by leading the fight against infections, and with this purpose and mindset, helping people in need is engrained in our corporate DNA. We are proud to be a main partner of SOS Children's Villages, Denmark, and we look forward to this new three-year collaboration, and our continued strong relationship commencing a third-term, where we are able to help those in most dire need."*

Mads Klæstrup Kristensen, Managing Director, SOS Children's Villages Denmark, commented: *"Our partnership with Xellia Pharmaceuticals is by far one of our most important and well-established, born out of a shared set of strong values."*

We are deeply grateful for this renewal of Xellia Pharmaceuticals' long-term commitment to creating positive change and socio-economic development in Eldoret – a commitment that is crucial to vulnerable families in the Family Strengthening Program and their children. We are immensely thankful for the support of Xellia Pharmaceuticals and are very happy to be able to continue our close collaboration.”

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com. Connect with us on [LinkedIn](#).